The Impact of Steroid Responder Status on Long-Term Outcomes in Critically Ill Patients With Acute Respiratory Distress Syndrome Receiving High-Dose Glucocorticoids

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 May 3

PMID 38699135

Authors

Thomas Leahy

Aneesha Chauhan

Victoria Nicholas

Pooja Patel

Alfred Wright

Samuel Miller

Geoff Ball

Christopher Remmington

Suveer Singh

Affiliations

Soon will be listed here.

Abstract

Background and objective High-dose intravenous pulsed glucocorticosteroids (GCS) are not part of the standard treatment in acute respiratory distress syndrome (ARDS), and the evidence supporting their use is conflicting. In clinical practice, however, they are used in specialist settings when clinico-patho-radiological features suggest a potentially steroid-responsive pattern, or as a last resort in cases where patients are unable to be weaned off mechanical ventilation. This study aimed to investigate if an early objective response to high-dose GCS treatment in selected critically ill patients is predictive of survival in ARDS. Methods This study involved a case series of 63 patients treated at a tertiary specialist respiratory ICU between 2009 and 2017 who received high-dose GCS for ARDS following a multidisciplinary board agreement. Patients were stratified according to the change in their modified lung injury score (mLIS) between days 0 and 10 following GCS initiation. Changes in mLIS (range: 0-4) were grouped as follows - full responders: ≥2, partial responders: ≥1 and <2, and non-responders: <1. Mortality on discharge and at 6, 12, 18, and 24 months post-ICU discharge was assessed for each group. Data were analysed using logistic regression and a receiver operating curve (ROC) to determine a statistically significant association between the change in mLIS and survival. Results Of the 63 patients, there were seven full responders, 12 partial responders, and 44 non-responders to high-dose GCS. Overall mortality at ICU discharge and 6, 12, 18 and 24 months post-discharge was 29/63 (46.0%), 33/63 (52.4%), 34/63 (54.0%), 34/63 (54.0%), and 35/63 (55.6%) respectively. Mortality was significantly lower in the partial and full-response groups than in the non-response group at all time frames. Logistic regression showed a significant association between the change in mLIS and survival (p<0.001), and a ROC demonstrated that categorising the change in mLIS was a good predictive model for survival (c-statistic 0.86). Conclusions Measuring the change in mLIS by day 10 following high-dose GCS administration for ARDS may be clinically useful in prognosticating such patients. Further research using mLIS as a measure of response to GCS, and larger datasets to enable the evaluation of prognostic factors, may assist clinicians in predicting which patients with persistent ARDS are likely to respond to GCS therapy.

References

Beasley M . The pathologist's approach to acute lung injury. Arch Pathol Lab Med. 2010; 134(5):719-27. DOI: 10.5858/134.5.719. View

Bihari S, Bailey M, Bersten A . Steroids in ARDS: to be or not to be. Intensive Care Med. 2015; 42(5):931-933. DOI: 10.1007/s00134-015-4135-0. View

Murray J, Matthay M, Luce J, Flick M . An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988; 138(3):720-3. DOI: 10.1164/ajrccm/138.3.720. View

Meduri G, Bridges L, Shih M, Marik P, Siemieniuk R, Kocak M . Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2015; 42(5):829-840. DOI: 10.1007/s00134-015-4095-4. View

Kangelaris K, Calfee C, May A, Zhuo H, Matthay M, Ware L . Is there still a role for the lung injury score in the era of the Berlin definition ARDS?. Ann Intensive Care. 2014; 4(1):4. PMC: 3931496. DOI: 10.1186/2110-5820-4-4. View

Arulkumaran N, Snow T, Longobardo A, Brealey D, Singer M . Steroids in ARDS: more light is being shed. Intensive Care Med. 2020; 46(11):2108-2110. PMC: 7471591. DOI: 10.1007/s00134-020-06230-z. View

Guerin C, Thompson T, Brower R . The ten diseases that look like ARDS. Intensive Care Med. 2014; 41(6):1099-102. DOI: 10.1007/s00134-014-3608-x. View

Malhotra A, Patel S . Lung biopsy in ARDS: is it worth the risk?. Crit Care. 2006; 10(4):160. PMC: 1750997. DOI: 10.1186/cc5001. View

Menk M, Estenssoro E, Sahetya S, Serpa Neto A, Sinha P, Slutsky A . Current and evolving standards of care for patients with ARDS. Intensive Care Med. 2020; 46(12):2157-2167. PMC: 7646492. DOI: 10.1007/s00134-020-06299-6. View

10.

Meduri G, Belenchia J, Estes R, Wunderink R, El Torky M, Leeper Jr K . Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest. 1991; 100(4):943-52. DOI: 10.1378/chest.100.4.943. View

11.

Silversides J, Ferguson N . Clinical review: Acute respiratory distress syndrome - clinical ventilator management and adjunct therapy. Crit Care. 2013; 17(2):225. PMC: 3672489. DOI: 10.1186/cc11867. View

12.

Meduri G, Headley A, Golden E, J Carson S, Umberger R, Kelso T . Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998; 280(2):159-65. DOI: 10.1001/jama.280.2.159. View

13.

Ware L, Matthay M . The acute respiratory distress syndrome. N Engl J Med. 2000; 342(18):1334-49. DOI: 10.1056/NEJM200005043421806. View

14.

Thompson B, Ranieri V . Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: no. Intensive Care Med. 2016; 42(5):921-923. PMC: 4829481. DOI: 10.1007/s00134-016-4255-1. View

15.

Ranieri V, Rubenfeld G, Thompson B, Ferguson N, Caldwell E, Fan E . Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23):2526-33. DOI: 10.1001/jama.2012.5669. View

16.

Steinberg K, Hudson L, Goodman R, Hough C, Lanken P, Hyzy R . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006; 354(16):1671-84. DOI: 10.1056/NEJMoa051693. View